US OKs first drug for dyskinaesia in Parkinson’s patients
Pharma times | August 25, 2017
US regulators have approved the first and only treatment option to treat dyskinaesia in patients with Parkinson's disease. The US Food and Drug Administration has cleared Adamas Pharmaceuticals’ Gocovri (amantadine; previously ADS-5102) extended release capsules for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy, with or without concomitant dopaminergic medications.